Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC-201 PET Study in Alzheimer's Disease
NCT02860065Phase 2Withdrawn
- Sponsor
- Allergan
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donepezil + solifenacin in Alzheimer's disease (AD), sponsored by Allergan. Planned start Sep 2016; status: withdrawn.
02
Drugs
donepezil + solifenacin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02860065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860065.